12 months in and triple agonist is still the thing I get wrong
Long-ish post, sorry. tl;dr at the bottom. I have been tracking retatrutide against triglycerides for 9 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab,…
Retitled to remove editorialising. Put the evidence in the body.
Retitled to remove editorialising.
Adding to this: TRIUMPH is doing more work than the comment implies.
Strongly agree. Heart rate escalation needs the actual data, not impressions.
the glucagon component changes the side effect profile, not just the efficacy
Not to be pedantic but dose escalation and phase 2 are being used interchangeably and they are not interchangeable in real life.
Retitled to remove editorialising.
Yes, exactly this, and it is the bit that took me 32 weeks to accept.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
You have restated the marketing copy. What is the actual substance here.